A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2023-07-31
Adverse events
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 9); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-03 (study day 15); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-08 (study day 20); relationship: Y
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-13 (study day 25); relationship: N
Grade 2 Diarrhoea — outcome: UNKNOWN; onset 2023-10-12 (study day 54); relationship: Y
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 75); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 75); relationship: N
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-02 (study day 75); relationship: N
Data queries
No data queries.